logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Panel Votes Against Astex Acute Myeloid Leukemia Drug Dacogen; Shares Down

Astex Pharmaceuticals, Inc. (ASTX) Thursday said the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee voted 10 to 3 against a favorable benefit-risk profile for Dacogen. The drug is indicated in the treatment of acute myeloid leukemia in adults 65 years of age or older who are not considered candidates for induction therapy.

Astex shares plunged over eight percent following the news. FDA has the option of seeking the advice of its advisory committees when reviewing a new drug application, although it is not obliged to follow the committee's recommendation. The PDUFA date is March 6, 2012.

The advisory committee reviewed data from Astex's partner Eisai whose supplemental New Drug Application or sNDA was accepted for FDA review in July 2011. The application is based on the open-label Phase III clinical trial (DACO-016) data.

DACO-016 trial was undertaken in 485 patients and compared Dacogen (decitabine) to a patient's treatment choice with physician advice of either supportive care or low-dose cytarabine in the treatment of older patients with acute myeloid leukemia. The primary endpoint of the study was overall survival.

The analysis demonstrated an increase of greater than 50 percent in median overall survival in patients taking decitabine, 7.7 months for decitabine patients compared to 5.0 months for patients in the comparator arm.

Astex developed Dacogen for Injection is approved in the United States for treatment of patients with myelodysplastic syndromes or MDS. Dacogen is currently approved for the treatment of MDS in about 30 countries. Dacogen is licensed to Eisai Co., Ltd and Eisai has licensed rights outside of North America to Janssen-Cilag International NV and other affiliates of Cilag GmbH International. Astex receives royalties on global sales of Dacogen.

In 2004, Astex granted Eisai exclusive worldwide rights to the development, manufacture, commercialization and distribution of Dacogen.

Astex has four products in or entering Phase II trials which are expected to produce clinical proof of concept data in the next 12 to 18 months.

In after-hours, ASTX is trading at $2.00, down $0.19 or 8.68%, on the Nasdaq. Over the past year, the stock traded in a range of $1.51 - $3.35.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Citigroup Inc. on Wednesday reported a 7 percent increase in profit for the fourth quarter from last year as lower revenues were more than offset by decreases in cost of credit as well as operating expenses. Adjusted earnings for the quarter beat analysts' expectations, while revenues missed their estimates. Goldman Sachs Group Inc. (GS) reported a profit for the fourth quarter that climbed from the previous year, while quarterly net revenues grew 12 percent. Net revenues in Fixed Income, Currency and Commodities Client Execution increased by 78 percent. Both earnings per share and revenues for the fourth-quarter topped analysts' expectations. Logan Green and John Zimmer, the co-founders of transportation network company Lyft, have come out with a vision to solve the traffic woes, including congestion-priced roads and carpooling. In a Medium post called "The End of Traffic," they said that companies like Lyft van join with the federal government to start various initiatives aimed encouraging more people to carpool.
comments powered by Disqus
Follow RTT